Shield Diagnostics Group, plc
This article was originally published in The Gray Sheet
Raises about $3.8 mil., net of expenses, in private placement of 499,361 new ordinary shares with institutional investors. Proceeds are tabbed for further commercialization of the Dundee, UK firm's Afecta (Activated Factor XII) and homocysteine cardiovascular tests, "including the development of new point-of-care diagnostics," the company states. The placement was arranged by Nomura International, plc
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.